Profil
Raymond Goodrich is the founder of PhotonPharma, Inc. and currently holds the title of CSO & Vice President-Research & Development at the company.
Postes actifs de Raymond Goodrich
| Sociétés | Poste | Début |
|---|---|---|
PhotonPharma, Inc.
 PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is developing the Innocell therapeutic cancer vaccine, which is a personalized therapy using autologous tumor tissue. The company is based in Fort Collins, CO at the Research Innovation Center of Colorado State University. The technology is based on a photochemical inactivation platform that uses riboflavin (vitamin B2) and UV light to render tumor cells incapable of replication while still allowing them to metabolize, express proteins, present antigens, and stimulate immune recognition and response mechanisms. In combination with selected adjuvants, Innocell has shown the ability to prevent metastatic tumor formation, reduce tumor growth, and stimulate cellular immune response pathways in preclinical animal models. The company was founded in 2018 by Raymond Goodrich, and Alan S. Rudolph has been the CEO since 2018. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
PhotonPharma, Inc.
PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is developing the Innocell therapeutic cancer vaccine, which is a personalized therapy using autologous tumor tissue. The company is based in Fort Collins, CO at the Research Innovation Center of Colorado State University. The technology is based on a photochemical inactivation platform that uses riboflavin (vitamin B2) and UV light to render tumor cells incapable of replication while still allowing them to metabolize, express proteins, present antigens, and stimulate immune recognition and response mechanisms. In combination with selected adjuvants, Innocell has shown the ability to prevent metastatic tumor formation, reduce tumor growth, and stimulate cellular immune response pathways in preclinical animal models. The company was founded in 2018 by Raymond Goodrich, and Alan S. Rudolph has been the CEO since 2018. | Health Technology |
